Acecainide (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Acecainide" in English language version.

refsWebsite

Global rank English rank

18nih.gov

4^th place

13doi.org

2^nd place

6semanticscholar.org

11^th place

8^th place

doi.org

Strong JM, Dutcher JS, Lee WK, Atkinson AJ (November 1975). "Absolute bioavailability in man of N-acetylprocainamide determined by a novel stable isotope method". Clinical Pharmacology and Therapeutics. 18 (5 Pt 1): 613–622. doi:10.1053/j.ajkd.2013.02.358. PMC 3851309. PMID 1183141.
Connolly SJ, Kates RE (1982). "Clinical pharmacokinetics of N-acetylprocainamide". Clinical Pharmacokinetics. 7 (3): 206–220. doi:10.2165/00003088-198207030-00002. PMID 6178545. S2CID 32155394.
Hollman A (February 1992). "Procaine and procainamide". British Heart Journal. 67 (2): 143. doi:10.1136/hrt.67.2.143. PMC 1024743. PMID 18610401.
Nylen ES, Cohen AI, Wish MH, Lima JJ, Finkelstein JD (January 1986). "Reduced acetylation of procainamide by para-aminobenzoic acid". Journal of the American College of Cardiology. 7 (1): 185–187. doi:10.1016/s0735-1097(86)80280-7. PMID 3484486. S2CID 2150893.
Evans DA (1989). "N-acetyltransferase". Pharmacology & Therapeutics. 42 (2): 157–234. doi:10.1016/0163-7258(89)90036-3. PMID 2664821.
Funck-Brentano C, Light RT, Lineberry MD, Wright GM, Roden DM, Woosley RL (September 1989). "Pharmacokinetic and pharmacodynamic interaction of N-acetyl procainamide and procainamide in humans". Journal of Cardiovascular Pharmacology. 14 (3): 364–373. doi:10.1097/00005344-198909000-00003. PMID 2476614. S2CID 27698759.
Sung RJ, Juma Z, Saksena S (May 1983). "Electrophysiologic properties and antiarrhythmic mechanisms of intravenous N-acetylprocainamide in patients with ventricular dysrhythmias". American Heart Journal. 105 (5): 811–819. doi:10.1016/0002-8703(83)90245-4. PMID 6189384.
Harron DW, Brogden RN (May 1990). "Acecainide (N-acetylprocainamide). A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in cardiac arrhythmias". Drugs. 39 (5): 720–740. doi:10.2165/00003495-199039050-00007. PMID 1693889. S2CID 46978066.
Mohamed AN, Abdelhady AM, Spencer D, Sowinski KM, Tisdale JE, Overholser BR (June 2013). "Pharmacokinetic modeling and simulation of procainamide and N-acetylprocainamide in a patient receiving continuous renal replacement therapy: a novel approach to guide renal dose adjustments". American Journal of Kidney Diseases. 61 (6): 1046–1048. doi:10.1053/j.ajkd.2013.02.358. PMC 3851309. PMID 23562328.
Olsen H, Mørland J (February 1982). "Ethanol-induced increase in procainamide acetylation in man". British Journal of Clinical Pharmacology. 13 (2): 203–208. doi:10.1111/j.1365-2125.1982.tb01357.x. PMC 1402013. PMID 7059417.
Atkinson AJ, Lee WK, Quinn ML, Kushner W, Nevin MJ, Strong JM (May 1977). "Dose-ranging trial of N-acetylprocainamide in patients with premature ventricular contractions". Clinical Pharmacology and Therapeutics. 21 (5): 575–587. doi:10.1002/cpt1977215575. PMID 322922. S2CID 22856741.
Kharidia J, Eddington ND (June 1996). "Application of computer-assisted radiotelemetry in the pharmacokinetic and pharmacodynamic modeling of procainamide and N-acetylprocainamide". Journal of Pharmaceutical Sciences. 85 (6): 595–599. doi:10.1021/js950473h. PMID 8773955.
Sun Q, Harper TW, Dierks EA, Zhang L, Chang S, Rodrigues AD, Marathe P (September 2011). "1-Aminobenzotriazole, a known cytochrome P450 inhibitor, is a substrate and inhibitor of N-acetyltransferase". Drug Metabolism and Disposition. 39 (9): 1674–1679. doi:10.1124/dmd.111.039834. PMID 21677062. S2CID 20848730.

nih.gov

pubmed.ncbi.nlm.nih.gov

Strong JM, Dutcher JS, Lee WK, Atkinson AJ (November 1975). "Absolute bioavailability in man of N-acetylprocainamide determined by a novel stable isotope method". Clinical Pharmacology and Therapeutics. 18 (5 Pt 1): 613–622. doi:10.1053/j.ajkd.2013.02.358. PMC 3851309. PMID 1183141.
Connolly SJ, Kates RE (1982). "Clinical pharmacokinetics of N-acetylprocainamide". Clinical Pharmacokinetics. 7 (3): 206–220. doi:10.2165/00003088-198207030-00002. PMID 6178545. S2CID 32155394.
Hollman A (February 1992). "Procaine and procainamide". British Heart Journal. 67 (2): 143. doi:10.1136/hrt.67.2.143. PMC 1024743. PMID 18610401.
Nylen ES, Cohen AI, Wish MH, Lima JJ, Finkelstein JD (January 1986). "Reduced acetylation of procainamide by para-aminobenzoic acid". Journal of the American College of Cardiology. 7 (1): 185–187. doi:10.1016/s0735-1097(86)80280-7. PMID 3484486. S2CID 2150893.
Evans DA (1989). "N-acetyltransferase". Pharmacology & Therapeutics. 42 (2): 157–234. doi:10.1016/0163-7258(89)90036-3. PMID 2664821.
Funck-Brentano C, Light RT, Lineberry MD, Wright GM, Roden DM, Woosley RL (September 1989). "Pharmacokinetic and pharmacodynamic interaction of N-acetyl procainamide and procainamide in humans". Journal of Cardiovascular Pharmacology. 14 (3): 364–373. doi:10.1097/00005344-198909000-00003. PMID 2476614. S2CID 27698759.
Sung RJ, Juma Z, Saksena S (May 1983). "Electrophysiologic properties and antiarrhythmic mechanisms of intravenous N-acetylprocainamide in patients with ventricular dysrhythmias". American Heart Journal. 105 (5): 811–819. doi:10.1016/0002-8703(83)90245-4. PMID 6189384.
Harron DW, Brogden RN (May 1990). "Acecainide (N-acetylprocainamide). A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in cardiac arrhythmias". Drugs. 39 (5): 720–740. doi:10.2165/00003495-199039050-00007. PMID 1693889. S2CID 46978066.
Mohamed AN, Abdelhady AM, Spencer D, Sowinski KM, Tisdale JE, Overholser BR (June 2013). "Pharmacokinetic modeling and simulation of procainamide and N-acetylprocainamide in a patient receiving continuous renal replacement therapy: a novel approach to guide renal dose adjustments". American Journal of Kidney Diseases. 61 (6): 1046–1048. doi:10.1053/j.ajkd.2013.02.358. PMC 3851309. PMID 23562328.
Bauer LA, Black D, Gensler A, Sprinkle J (May 1989). "Influence of age, renal function and heart failure on procainamide clearance and n-acetylprocainamide serum concentrations". International Journal of Clinical Pharmacology, Therapy, and Toxicology. 27 (5): 213–216. PMID 2472362.
Olsen H, Mørland J (February 1982). "Ethanol-induced increase in procainamide acetylation in man". British Journal of Clinical Pharmacology. 13 (2): 203–208. doi:10.1111/j.1365-2125.1982.tb01357.x. PMC 1402013. PMID 7059417.
Atkinson AJ, Lee WK, Quinn ML, Kushner W, Nevin MJ, Strong JM (May 1977). "Dose-ranging trial of N-acetylprocainamide in patients with premature ventricular contractions". Clinical Pharmacology and Therapeutics. 21 (5): 575–587. doi:10.1002/cpt1977215575. PMID 322922. S2CID 22856741.
Kharidia J, Eddington ND (June 1996). "Application of computer-assisted radiotelemetry in the pharmacokinetic and pharmacodynamic modeling of procainamide and N-acetylprocainamide". Journal of Pharmaceutical Sciences. 85 (6): 595–599. doi:10.1021/js950473h. PMID 8773955.
Sun Q, Harper TW, Dierks EA, Zhang L, Chang S, Rodrigues AD, Marathe P (September 2011). "1-Aminobenzotriazole, a known cytochrome P450 inhibitor, is a substrate and inhibitor of N-acetyltransferase". Drug Metabolism and Disposition. 39 (9): 1674–1679. doi:10.1124/dmd.111.039834. PMID 21677062. S2CID 20848730.

ncbi.nlm.nih.gov

Strong JM, Dutcher JS, Lee WK, Atkinson AJ (November 1975). "Absolute bioavailability in man of N-acetylprocainamide determined by a novel stable isotope method". Clinical Pharmacology and Therapeutics. 18 (5 Pt 1): 613–622. doi:10.1053/j.ajkd.2013.02.358. PMC 3851309. PMID 1183141.
Hollman A (February 1992). "Procaine and procainamide". British Heart Journal. 67 (2): 143. doi:10.1136/hrt.67.2.143. PMC 1024743. PMID 18610401.
Mohamed AN, Abdelhady AM, Spencer D, Sowinski KM, Tisdale JE, Overholser BR (June 2013). "Pharmacokinetic modeling and simulation of procainamide and N-acetylprocainamide in a patient receiving continuous renal replacement therapy: a novel approach to guide renal dose adjustments". American Journal of Kidney Diseases. 61 (6): 1046–1048. doi:10.1053/j.ajkd.2013.02.358. PMC 3851309. PMID 23562328.
Olsen H, Mørland J (February 1982). "Ethanol-induced increase in procainamide acetylation in man". British Journal of Clinical Pharmacology. 13 (2): 203–208. doi:10.1111/j.1365-2125.1982.tb01357.x. PMC 1402013. PMID 7059417.

semanticscholar.org

api.semanticscholar.org

Connolly SJ, Kates RE (1982). "Clinical pharmacokinetics of N-acetylprocainamide". Clinical Pharmacokinetics. 7 (3): 206–220. doi:10.2165/00003088-198207030-00002. PMID 6178545. S2CID 32155394.
Nylen ES, Cohen AI, Wish MH, Lima JJ, Finkelstein JD (January 1986). "Reduced acetylation of procainamide by para-aminobenzoic acid". Journal of the American College of Cardiology. 7 (1): 185–187. doi:10.1016/s0735-1097(86)80280-7. PMID 3484486. S2CID 2150893.
Funck-Brentano C, Light RT, Lineberry MD, Wright GM, Roden DM, Woosley RL (September 1989). "Pharmacokinetic and pharmacodynamic interaction of N-acetyl procainamide and procainamide in humans". Journal of Cardiovascular Pharmacology. 14 (3): 364–373. doi:10.1097/00005344-198909000-00003. PMID 2476614. S2CID 27698759.
Harron DW, Brogden RN (May 1990). "Acecainide (N-acetylprocainamide). A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in cardiac arrhythmias". Drugs. 39 (5): 720–740. doi:10.2165/00003495-199039050-00007. PMID 1693889. S2CID 46978066.
Atkinson AJ, Lee WK, Quinn ML, Kushner W, Nevin MJ, Strong JM (May 1977). "Dose-ranging trial of N-acetylprocainamide in patients with premature ventricular contractions". Clinical Pharmacology and Therapeutics. 21 (5): 575–587. doi:10.1002/cpt1977215575. PMID 322922. S2CID 22856741.
Sun Q, Harper TW, Dierks EA, Zhang L, Chang S, Rodrigues AD, Marathe P (September 2011). "1-Aminobenzotriazole, a known cytochrome P450 inhibitor, is a substrate and inhibitor of N-acetyltransferase". Drug Metabolism and Disposition. 39 (9): 1674–1679. doi:10.1124/dmd.111.039834. PMID 21677062. S2CID 20848730.